SHINVA Showcases at ESTRO 2025

Vienna, Austria – May 2–5, 2025 — SHINVA, a leading manufacturer of high-end medical equipment from China, made a strong impression at the European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting 2025, one of the most prestigious global events in the field of radiotherapy.

At this year’s ESTRO, SHINVA unveiled three of its latest core innovations:

  • Tai’a Intelligent Ring-Type Online Adaptive Radiotherapy System
  • Dual-Photon Volumetric Modulated Arc Therapy (VMAT) System
  • Large-Bore Simulation CT Scanner

These cutting-edge technologies embody SHINVA’s dedication to precision oncology and mark significant advancements in intelligent, adaptive radiotherapy. Their debut captured the attention of international experts and industry professionals alike.

SHINVA

Driving Innovation in Precision Radiotherapy

During the event, SHINVA’s expert team engaged extensively with radiotherapy specialists from around the world. They presented the performance benefits and clinical usability of SHINVA’s solutions, shared the company’s latest research progress in adaptive radiotherapy, and collected valuable feedback from global users to further optimize product development.

One of the highlights was the Tai’a Intelligent Ring-Type Online Adaptive Radiotherapy System, developed entirely in-house by SHINVA. Key features include:

  • A dual-layer interleaved high-speed multileaf collimator (MLC)
  • A coaxial and coplanar high-definition onboard imaging system
  • SHINVA’s proprietary 6MV beam generation platform

This system supports dual-dose output modes (2F and 3F), enabling advanced techniques such as:

  • Rapid volumetric intensity modulation
  • High-precision stereotactic radiotherapy
  • 15-minute online adaptive treatments

These capabilities represent a significant leap forward in integrating efficiency, precision, and adaptability into clinical radiotherapy workflows.

Empowering Global Access to Chinese Innovation

SHINVA’s presence at ESTRO 2025 not only showcased its technological capabilities but also marked a milestone in the internationalization of China’s high-end radiotherapy solutions. Competing alongside the world’s leading manufacturers, SHINVA reaffirmed its position as a rising global force in cancer treatment innovation.

By fostering close collaborations with top-tier global experts and institutions, SHINVA continues to expand the clinical accessibility of advanced radiotherapy technologies—bringing tangible benefits to cancer patients worldwide.

Looking Ahead

SHINVA remains committed to innovation-driven development and clinical need-oriented design, with a mission to deliver high-quality radiotherapy solutions to healthcare providers around the globe. Through continuous breakthroughs in technology, SHINVA aims to empower more patients to benefit from the growing potential of precision medicine.

See all news